- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prostate cancer
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1567KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 2085KB)
Darolutamide – March 2021
Darolutamide: Tablet 300 mg; Nubeqa®
Last updated
2 July 2021